Take orally once daily in the evening, with or without food. For asthma, take in the evening. For allergic rhinitis, timing may be adjusted to suit patient needs. For exercise-induced bronchoconstriction, take at least 2 hours before exercise, not to exceed once daily.

Montelukast selectively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, which prevents the bronchoconstrictor, pro-inflammatory, and other effects of leukotrienes. Leukotrienes are potent inflammatory mediators released from various cells, including mast cells and eosinophils, involved in asthma and allergic rhinitis.

• •Hypersensitivity to Montelukast or any component of the formulation.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose often include abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Treatment is symptomatic and supportive. No specific antidote is known.

Pregnancy category B. Use during pregnancy only if clearly needed. Montelukast is excreted in breast milk; caution should be exercised when administered to a nursing woman.